Arexvy RSV Vaccine (Extended Protection Study)
RSV Prevention in Older Adults
SponsorGSK
12,000Enrollment Target
200Trial Sites
5Countries
March 2027Est. Completion
About This Trial
Evaluating duration of protection and need for revaccination with approved RSV vaccine.
Primary Endpoints
- Efficacy against RSV-LRTD at Season 3
- Immunogenicity persistence
Latest Update
February 2026
Season 2 efficacy of 67% against RSV-LRTD maintained. Single dose may provide multi-season protection.